Skip to main content

Ligand Pharmaceuticals Incorporated

corporate_fare Company Profile

Ligand Pharmaceuticals Incorporated

LGND·NASDAQ·Life Sciences·CIK 0000886163

Ligand Pharmaceuticals Incorporated is a biopharmaceutical royalty company that acquires and creates diversified royalty streams from high-value medicines by deploying capital and licensing technologies. The company primarily invests in and structures royalty interests in mid- to late-stage development and commercial biopharmaceutical products to generate long-duration, non-dilutive cash flows with a lean corporate cost structure. Capital deployment and technology licensing drive long-term growth. Ligand partners capital through royalty purchases, development-stage financing arrangements, and acquisitions of companies or assets with embedded royalty rights to create cash-flowing royalties. In addition to royalty investment activities, Ligand operates two infrastructure-light, royalty-generating platform technologies: Captisol® and NITRICIL®. These technologies have existing royalty streams and potential for incremental royalties through partner-driven development and commercialization. Revenue is primarily generated from royalties on sales of products commercialized by partners, supplemented by Captisol material sales and contract revenue from license fees and milestone payments. Ligand partners with biopharmaceutical companies for late-stage development, regulatory execution, and commercialization, while focusing on capital deployment, portfolio construction, and risk management, leveraging partners' infrastructure to avoid high costs. Ligand is a biopharmaceutical royalty aggregator, focusing on disciplined capital allocation to differentiated late-stage assets and operating royalty-generating, infrastructure-light platform technologies. The company has 12 major commercial stage royalty assets, which comprise the majority of its royalty revenue. Ligand maintains a portfolio of more than 90 additional commercial and development-stage programs. In 2022, Ligand refined its strategy to focus on a more efficient, high margin, low infrastructure version of its historical model.

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 32 items for LGND at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-30, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for LGND spans 10-Q, 8-K, 8-K/A.

Recent high-impact activity:

  • Ligand 10-Q Details Q3 Loss, 51% Royalty Growth and $460M Notes Now Current
  • Ligand Q3 Adjusted EPS Beats at $2.67 as Revenue Jumps 71.5% to $149M
  • Ligand Q3 Royalties Up 51% to $70.3M, Raises 2026 Adjusted EPS Guidance
  • Ligand Posts $1.43 Per-Share Q3 Loss as Royalty Story Faces First Test
  • Ligand Commits Up to $47M to AvenCell for Royalty on Next-Gen CAR-T Pipeline

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$268.09M
Net Income
$124.45M
Diluted EPS
$6.13
Op. Cash Flow
$49.36M
Free Cash Flow
$48.91M
Operating Income
$41M
Cash & Equivalents
$174.93M
Total Debt
$446.19M
Debt / Equity
0.44×
Net Margin
46.4%
Shares Outstanding
19.77M sh
Source: 10-K · filed 2026-02-27 · accession 0000886163-26-000006

Short Interest & Short Volume

10.53 days to cover

FINRA reported short interest of 2,464,093 shares in LGND as of the October 30, 2026 settlement, a 1.5% decrease from the prior period — about 10.5 days to cover at its recent average daily volume. On November 20, 2026, 80.6% of LGND volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)2,464,093 shares as of October 30, 2026
Change vs prior period▼ 1.5%
Days to cover10.53 at avg daily volume of 234,088
Daily short volume (FINRA facilities)80.6% of 69,882 shares on November 20, 2026
5-day average short volume65.8%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for LGND, detected from its recent SEC filings · based on capital-structure filings through 2026-06-25.

Upsized Convertible Notes Offering Closed · Favorable Conversion and Warrant Pricing

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Recent Capital Actions

  • 2026-02-27 Proposed ATM Program $100M

    per share, offered pursuant to this prospectus and the accompanying prospectus. In accordance with the terms of the Sales Agreement, we may offer and sell shares of our common stock having an aggregate offering price of…

Detected from SEC filings (8-K, S-4, POS AM, 6-K). Last 12 months.
Browse all tickers starting with L →
$286.85
52-week range · as of 2026-10-30 $175.89 – $326.63
Market cap
$5.74B
Volume
259.8K (1.2× avg)
3-mo avg 223.2K
Live data · 2026-11-22 12:43 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed LGND - Latest Insights

LGND
Oct 30, 2026, 4:47 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $324.00
Real-time Price: $286.85 info
Change: -$37.15 (-11%) info
Market Cap: $5.738B info
LGND
Oct 29, 2026, 3:12 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $316.21
Real-time Price: $286.85 info
Change: -$29.36 (-9%) info
Market Cap: $5.738B info
LGND
Oct 29, 2026, 7:14 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $311.87
Real-time Price: $286.85 info
Change: -$25.02 (-8%) info
Market Cap: $5.738B info
LGND
Oct 29, 2026, 7:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $311.87
Real-time Price: $286.85 info
Change: -$25.02 (-8%) info
Market Cap: $5.738B info
LGND
Sep 24, 2026, 7:15 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $298.41
Real-time Price: $286.85 info
Change: -$11.56 (-4%) info
Market Cap: $5.738B info
LGND
Sep 22, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $290.00
Real-time Price: $286.85 info
Change: -$3.15 (-1%) info
Market Cap: $5.738B info
LGND
Sep 02, 2026, 4:08 PM EDT
Filing Type: 8-K/A
Importance Score:
7
Price at Filing: $286.92
Real-time Price: $286.85 info
Change: -$0.070 (-0.02%) info
Market Cap: $5.738B info
LGND
Aug 07, 2026, 4:06 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $290.00
Real-time Price: $286.85 info
Change: -$3.15 (-1%) info
Market Cap: $5.738B info
LGND
Aug 06, 2026, 7:26 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $302.00
Real-time Price: $286.85 info
Change: -$15.15 (-5%) info
Market Cap: $5.738B info
LGND
Aug 06, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $302.00
Real-time Price: $286.85 info
Change: -$15.15 (-5%) info
Market Cap: $5.738B info
LGND
Jul 14, 2026, 9:20 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $309.31
Real-time Price: $286.85 info
Change: -$22.46 (-7%) info
Market Cap: $5.738B info
LGND
Jun 30, 2026, 4:00 AM EDT
Source: MFN by Modular Finance
Importance Score:
7
Price at Filing: $308.00
Real-time Price: $286.85 info
Change: -$21.15 (-7%) info
Market Cap: $5.738B info
LGND
Jun 25, 2026, 5:00 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $295.92
Real-time Price: $286.85 info
Change: -$9.07 (-3%) info
Market Cap: $5.738B info
LGND
Jun 25, 2026, 4:01 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $295.92
Real-time Price: $286.85 info
Change: -$9.07 (-3%) info
Market Cap: $5.738B info
LGND
Jun 23, 2026, 4:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $267.87
Real-time Price: $286.85 info
Change: +$18.98 (+7%) info
Market Cap: $5.738B info
LGND
Jun 23, 2026, 3:13 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $262.17
Real-time Price: $286.85 info
Change: +$24.68 (+9%) info
Market Cap: $5.738B info
LGND
Jun 22, 2026, 7:11 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $266.33
Real-time Price: $286.85 info
Change: +$20.52 (+8%) info
Market Cap: $5.738B info
LGND
Jun 22, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $266.33
Real-time Price: $286.85 info
Change: +$20.52 (+8%) info
Market Cap: $5.738B info
LGND
Jun 09, 2026, 4:02 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $243.28
Real-time Price: $286.85 info
Change: +$43.57 (+18%) info
Market Cap: $5.738B info
LGND
May 08, 2026, 4:14 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $221.41
Real-time Price: $286.85 info
Change: +$65.44 (+30%) info
Market Cap: $5.738B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets